Ok
Данный  веб-сайт использует собственные файлы cookie, чтобы сделать его посещение  как можно более удобным, о чём мы информируем , согласно /RGPD/ - Европейского регламента о защите данных потребителей .  Если вы продолжите пользоваться нашими услугами, мы будем считать, что вы даёте согласие на использование файлов cookie. Здесь вы можете найти дополнительную информацию о файлах cookie и о том, как от них отказаться.
Главная \ Scientific research

Scientific research

  • Guryanova SV and Khaitov RM (2021) Strategies for Using Muramyl Peptides - Modulators of Innate Immunity of Bacterial Origin - in Medicine. Front. Immunol. 12:607178. doi: 10.3389/fimmu.2021.607178

https://www.frontiersin.org/articles/10.3389/fimmu.2021.607178/full


  • Guryanova S.V., Kudryashova N.A., Kataeva A.A., Orozbekova B.T., Kolesnikova N.V., Chuchalin A.G. (2021) Novel approaches to increase resistance to acute respiratory infections Journal: RUDN Journal of Medicine (Vol.25, No. 3) 2021-10-03 Page: 181-195 

http://journals.rudn.ru/medicine/article/view/27534


  • Abramashvili Yu. G., Kolesnikova N.V., Borisova O. Yu., Guryanova S.V. Low molecular weight bioregulator of bacterial origin in condylomatosis therapy optimization. RUDN Journal of Medicine. 2020 Mar; 24 (2): 163–167. DOI:10.22363/2313-0245-2020-24-2-163-167

http://journals.rudn.ru/medicine/article/view/23812/18242


  • Konorev M.R., Guryanova S.V., Tyshevich E.N., Pavlyukov R.A., Borisova O.Yu. Advisable including glucosaminylmuramyldipeptide in Helicobacter pylori therapy: experience of ten-year investigation. RUDN Journal of Medicine. 2020 Mar; 24 (3):269—282. DOI: 10.22363/2313-0245-2020-24-3-269-282

http://journals.rudn.ru/medicine/article/view/24442/18514


  • Guryanova S, Udzhukhu V, Kubylinsky A. Pathogenetic Therapy of Psoriasis by Muramyl Peptide. Front Immunol. 2019 Jun 20;10:1275. doi: 10.3389/fimmu.2019.01275

https://www.frontiersin.org/articles/10.3389/fimmu.2019.01275/full


  • The results of the study of the carcinogenic properties of glucosaminylmuramyldipeptide GMDP in chronic experiments in mice and rats. Research Results in Pharmacology 4(4): 97–106 UDC: 615.37:616-006:636.028 DOI 10.3897/rrpharmacology.4.32191

https://rrpharmacology.pensoft.net/article/32191/


  • Laman AG, Lathe R, Shepelyakovskaya AO, Gartseva A, Brovko FA, Guryanova S, Alekseeva L, Meshcheryakova EA, Ivanov VT.  Muramyl peptides activate innate immunity conjointly via YB1 and NOD2. 2. Innate Immun. 2016 Nov;22(8):666-673. doi: 10.1177/1753425916668982

https://journals.sagepub.com/doi/pdf/10.1177/1753425916668982


  • Nikitushkin VD, Demina GR, Shleeva MO, Guryanova SV, Ruggiero A, Berisio R, Kaprelyants AS. A product of RpfB and RipA joint enzymatic action promotes the resuscitation of dormant mycobacteria. FEBS J. 2015 Jul;282(13):2500-11. doi: 10.1111/febs.1329

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1111/febs.13292


  • Meshcheryakova, E. A., Mineev, K. S., Volynski, P. E., Andronova, T. M., and Ivanov, V. T. (2015) GMDP: unusual physico-chemical and biological properties of the anomeriс forms. J. Pept. Sci., 21: 717– 722. doi: 10.1002/psc.2796.

https://pubmed.ncbi.nlm.nih.gov/26153038/


  • Laman AG, Lathe R, Savinov GV, Shepelyakovskaya AO, Boziev KhM, Baidakova LK, Chulin AN, Brovko FA, Svirshchevskaya EV, Kotelevtsev Y, Eliseeva IA, Guryanov SG, Lyabin DN7, Ovchinnikov LP, Ivanov VT. Innate immunity: Bacterial cell-wall muramyl peptide targets the conserved transcription factor YB-1. FEBS Lett. 2015 Jul 8;589(15):1819-24. doi: 10.1016/j.febslet.2015.05.028

https://febs.onlinelibrary.wiley.com/doi/full/10.1016/j.febslet.2015.05.028


  • Savinov GV, Shepelyakovskaya AO, Boziev KhM, Brovko FA, Laman AG. Search for ligand of N-acetylglucosaminyl-N-acetylmuramyl dipeptide using its peptide mimetic. Biochemistry (Mosc). 2014 Feb;79(2):131-8. doi: 10.1134/S0006297914020060

http://protein.bio.msu.ru/biokhimiya/contents/v79/full/79020178.html


  • Antsiferova Y, Sotnikova N, Parfenyuk E. Different effects of the immunomodulatory drug GMDP immobilized onto aminopropyl modified and unmodified mesoporous silica nanoparticles upon peritoneal macrophages of women with endometriosis. Biomed Res Int. 2013;2013:924362. doi: 10.1155/2013/924362

https://www.hindawi.com/journals/bmri/2013/924362/


  • Meshcheryakova E, Makarov E, Philpott D, Andronova T, Ivanov V. Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N-acetylglucosaminyl-N-acetylmuramyl peptides. Vaccine. 2007 Jun 6;25(23):4515-20. doi: 10.1016/j.vaccine.2007.04.006.

https://pubmed.ncbi.nlm.nih.gov/17481783/


  • D. Williamson, M. Chawla, R. Marks. GMDP for psoriasis. THE LANCET, August 1998, Volume 352, Issue 9127, Page 545

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/0014-5793%2894%2901219-9


  • Valyakina TI1, Komaleva RL, Petrova EE, Malakhov AA, Shamborant OG, Andronova TM, Nesmeyanov VA.  Endogenous tumour necrosis factor-alpha sensitise melanoma cells to glucosaminylmuramyl dipeptide. FEBS Lett. 1998 Apr 24;426(3):373-6.

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/S0014-5793%2898%2900376-7


  • Mareeva TYu1, Kotova OV, Golovina TN, Nesmeyanov VA. Production and characterization of monoclonal anti-idiotypic antibodies to muramylpeptide. FEBS Lett. 1994 Dec 12;356(1):13-6.

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/0014-5793%2894%2901220-2


  • Sumaroka MV1, Litvinov IS, Khaidukov SV, Golovina TN, Kamraz MV, Komal'eva RL, Andronova TM, Makarov EA, Nesmeyanov VA, Ivanov VT. Muramyl peptide-binding sites are located inside target cells. FEBS Lett. 1991 Dec 16;295(1-3):48-50.

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/0014-5793%2891%2981381-H


  • Kaydalov AA, Utkin YuN, Andronova TM, Tsetlin VI, Ivanov VT. Muramyl peptides bind specifically to rat brain membranes.FEBS Lett. 1989 May 8;248(1-2):78-82.

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/0014-5793%2889%2980435-1